Purple Biotech Presents New IM1240 Cancer Antibody Data in Barcelona

Rehovot based Purple Biotech announced new presentation data for its experimental antibody IM1240 on November 20 at the EORTC-NCI-AACR cancer symposium in Barcelona. The findings come from tumor samples and animal studies.
The research asks whether recruiting immune cells to a tumor is enough. Purple's approach also tries to remove an inhibitory signal that can restrain those cells, while keeping part of the antibody inactive until it reaches conditions associated with the tumor.
Three Functions in One Antibody
IM1240 is the lead candidate in the company's CAPTN-3 platform. According to Purple, one arm binds the tumor associated antigen 5T4, another engages T cells through CD3, and a third engages NKG2A, an inhibitory immune checkpoint affecting natural killer cells and some T cells.
The CD3 arm carries a removable cap. The design is intended to keep it inactive in circulation and allow enzymes in the tumor environment to uncover it.
What the Tumor Samples Showed
The company said the presentation included six metastatic lymph node samples from head and neck cancer, one muscle invasive bladder cancer sample and one non-small cell lung cancer sample. These were patient derived specimens collected after prior treatment.
In the lung tumor explant, Purple reported a pathologic response score of 94 on a scale from 0 to 100. An otherwise comparable antibody with an inactive NKG2A binding arm scored 49; preventing CD3 activation with a permanent cap reduced the score to 38.
The comparison shows what each component contributes within this experimental model. Our guide to finding original Israeli scientific research explains why the study type matters when reading a headline.
A Separate Test of the Cap
Purple also described nonhuman primate studies comparing capped and uncapped antibodies. It reported reduced cytokine release with the capping approach, alongside approximately eight times the half life and 16 times the systemic exposure.
The work was presented by Mount Sinai immunologist Amir Horowitz, whose research examines inhibitory signals within tumors.
Moving Toward Clinical Development
The new presentation builds on data shown at the EACR congress in June. Purple says IM1240 is moving toward clinical development.
The data adds to a busy month for Israeli cancer research, which also brought the Ichilov and Masaryk research agreement.



